We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Rubius Therapeutics Inc | NASDAQ:RUBY | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.083 | 0.0888 | 0.0894 | 0 | 01:00:00 |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 4 | | | |
| | | | 6 | | | |
| | | | 9 | | | |
| | | | 10 | | | |
| | | | 10 | | | |
| | | | 10 | | | |
| | | | A-1 | | |
| | |
As of
May 31, 2022 |
| |
Upon
Effectiveness of Amendment |
| ||||||
TOTAL AUTHORIZED SHARES OF COMMON STOCK
|
| | | | 150,000,000 | | | | | | 300,000,000 | | |
Outstanding shares of Common Stock
|
| | | | 90,357,032 | | | | | | 90,357,032 | | |
Shares of Common Stock authorized for future issuance under the Company’s incentive plans
|
| | | | 3,811,343 | | | | | | 3,811,343 | | |
Shares of Common Stock authorized for future issuance under the Company’s employee stock purchase plan
|
| | | | 1,573,486 | | | | | | 1,573,486 | | |
Shares of Common Stock subject to outstanding equity awards under the Company’s incentive plans
|
| | | | 20,772,701 | | | | | | 20,772,701 | | |
TOTAL OUTSTANDING SHARES OF COMMON STOCK, SHARES OF
COMMON STOCK SUBJECT TO OUTSTANDING EQUITY AWARDS AND OPTIONS, AND SHARES OF COMMON STOCK AUTHORIZED FOR FUTURE ISSUANCE UNDER THE COMPANY’S INCENTIVE AND EMPLOYEE STOCK PURCHASE PLANS |
| | |
|
116,514,562
|
| | | |
|
116,514,562
|
| |
SHARES OF COMMON STOCK AVAILABLE FOR ISSUANCE
|
| | | | 33,485,438 | | | | | | 183,485,438 | | |
| | |
Shares beneficially owned
|
| |||||||||
Name and address of beneficial owner
|
| |
Number
|
| |
Percentage
|
| ||||||
5% Stockholders: | | | | | | | | | | | | | |
Entities affiliated with the Flagship Pioneering Funds(1)
|
| | | | 38,506,526 | | | | | | 42.6% | | |
FMR LLC(2)
|
| | | | 13,479,866 | | | | | | 14.9% | | |
Baillie Gifford & Co(3)
|
| | | | 4,930,859 | | | | | | 5.5% | | |
Named Executive Officers and Directors: | | | | | | | | | | | | | |
Pablo J. Cagnoni, M.D.(4)
|
| | | | 4,336,291 | | | | | | 4.6% | | |
Jose Carmona(5)
|
| | | | 175,000 | | | | | | * | | |
Dannielle Appelhans(6)
|
| | | | — | | | | | | * | | |
Maiken Keson-Brookes(7)
|
| | | | 190,030 | | | | | | * | | |
Laurence Turka, M.D.(8)
|
| | | | 272,889 | | | | | | * | | |
Noubar B. Afeyan, Ph.D.(9)
|
| | | | 38,606,526 | | | | | | 42.7% | | |
Francis Cuss, M.B., B.Chir., FRCP(10)
|
| | | | 240,000 | | | | | | * | | |
David R. Epstein(11)
|
| | | | 7,700,827 | | | | | | 8.3% | | |
Natalie Holles(5)
|
| | | | 100,000 | | | | | | * | | |
Anne Prener, M.D., Ph.D.(5)
|
| | | | 66,666 | | | | | | * | | |
Michael Rosenblatt, M.D.(5)
|
| | | | 250,000 | | | | | | * | | |
Catherine A. Sohn, Pharm.D.(12)
|
| | | | 232,500 | | | | | | * | | |
Sir Jonathan R. Symonds, CBE(13)
|
| | | | 295,000 | | | | | | * | | |
All executive officers and directors as a group (13 persons)(14)
|
| | | | 52,465,729 | | | | | | 52.8% | | |
1 Year Rubius Therapeutics Chart |
1 Month Rubius Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions